Why the study?
Polymorphisms of the CD36 gene may influence atherosclerotic changes, but confirmation of their prognostic value over long-term follow-up was needed.
Do selected polymorphisms in the CD36 gene predict long-term cardiovascular outcomes in patients with early-onset CAD?
Do selected polymorphisms in the CD36 gene predict long-term cardiovascular outcomes in patients with early-onset CAD?
Selected polymorphisms in the CD36 gene do not appear to have prognostic value for long-term cardiovascular outcomes in Caucasian patients with early-onset CAD.
Answers are grounded in this paper and cite their sources.
CD36 variants lack prognostic value in early-onset CAD; leaves open whether other genetic markers predict long-term outcomes.
The polymorphism of the CD36 gene may have a decisive impact on the formation and progression of atherosclerotic changes. The aim of the study was to confirm the prognostic values of the previously studied polymorphisms in the CD36 gene within a 10-year follow-up period. This is the first published report confirming the long-term observation of patients with CAD. The study group covered 100 early-onset CAD patients. It included 26 women not older than 55 years and 74 men not older than 50 years, tested in a ten-year study as a long-term follow-up after the first cardiovascular episode. There are no notable differences between the CD36 variants and the number of fatalities during observation, fatalities due to cardiological reasons, cases of myocardial infarction within a ten-year observation period, hospitalizations for cardiovascular issues, all cardiovascular occurrences, and the number of months lived. We have shown that the CD36 variants analyzed in this study do not appear to be related to the risk of early CAD occurrence in the Caucasian population in long-term observation.
No takes yet. Share an insight, caveat, or question.
Bartoszewicz et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: